NeXstar Creates Aptamer-Based Diagnostic Assay; Assay Aids Clinical Development Of VEGF Inhibitor

August 06, 1996

NeXstar Creates Aptamer-Based Diagnostic Assay; Assay Aids Clinical Development of VEGF Inhibitor
Contact: Joseph Alper
Director, Corporate Communications
(303) 546-7717

NeXstar Creates Aptamer-Based Diagnostic Assay; Assay Aids Clinical Development of VEGF Inhibitor

BOULDER, COLORADO, AUGUST 6, 1996 -- NeXstar Pharmaceuticals, Inc., (NASDAQ:NXTR) announced today that it has successfully developed a new analytical method that uses aptamers to detect small amounts of clinically important substances. This technique, named the enzyme-linked oligonucleotide assay, or ELONA, not only has applications in standardized-format clinical assays, but is also playing an important role in the Company's on-going development of its angiogenesis inhibitors as anti-cancer agents. Aptamers are short, rigid oligonucleotides that recognize target molecules with high affinity. NeXstar Pharmaceuticals is creating aptamers for both therapeutic and diagnostic applications using its patented SELEX combinatorial chemistry process.

The August issue of the journal Nature Biotechnology has published an article describing the ELONA system, in which an aptamer replaces an antibody in the enzyme-linked assay diagnostic assay format known as ELISA. The article, titled "An enzyme-linked oligonucleotide assay," was authored by Daniel W. Drolet, Ph.D., Lotus Moon-McDermott and Timothy S. Romig, all of NeXstar Pharmaceuticals.

In a typical ELISA, one antibody is used to capture the substance to be measured and anchor it to a surface, typically in a microtiter plate. A second antibody, coupled to a detect reagent, is then added and is used to measure the quantity of substance present. Antibodies, while excellent diagnostic reagents in general, do have limitations. Some target molecules are poorly immunogenic or toxic, making it difficult or impossible to raise an antibody. The large size and complexity of a typical antibody can make it difficult to modify the antibody with the reagents needed for detection or can interfere with the speed with which the assay can be run.

In the current work, Dr. Drolet and his colleagues used an aptamer that binds specifically and tightly to human vascular endothelial growth factor (VEGF), a protein secreted by tumors that triggers the growth of new blood vessels. The aptamer was modified by attaching a reagent used frequently in ELISA to measure the amount of binding that occurs, and it was then used as the detect reagent. Measures of precision, accuracy, interference, and specificity showed that this aptamer-based assay was equivalent to a typical ELISA using an antibody as the detect reagent. It should be possible to develop an aptamer that would replace the capture antibody, too.

"This paper demonstrates the utility of aptamers generated using our SELEX process in an important diagnostic format," said Barry A. Polisky, Ph.D., NeXstar Pharmaceuticals' Vice President for Drug Discovery. "This performance, coupled with the advantages that aptamers have over monoclonal antibodies, suggests that aptamers may have important applications in the diagnostic arena." Last week, NeXstar Pharmaceuticals and Roche Molecular Systems signed a research and development agreement that calls for NeXstar Pharmaceuticals to develop an aptamer for use in the PCR DNA amplification process.

In addition, the Company believes that the VEGF ELONA will play an important role in the clinical development of its VEGF antagonist, a compound that has already demonstrated promising in vitro and in vivo activity. There is a large body of published data demonstrating that tumor-directed angiogenesis is a heterogeneous process: not all tumors trigger blood vessel growth using the same angiogenesis factor. This heterogeneity means that not all cancer patients may be candidates for treatment with a drug directed against one specific angiogenesis factor. Thus, the Company's parallel development of the VEGF ELONA and a therapeutic based on an anti-VEGF aptamer may improve the design of clinical trials that will test the efficacy of such an aptamer. The Company is also developing inhibitors of other angiogenesis factors, including PDGF, TGF-beta and the integrin alpha-v-beta-3, and will create ELONAs for each of these antagonists as needed.

NeXstar Pharmaceuticals, Inc. is an integrated pharmaceutical company engaged in the discovery, development, manufacturing and marketing of products to treat life-threatening diseases. The Company currently markets two drugs, AmBisome and DaunoXome. The Company has headquarters in Boulder, Colorado; research, development and manufacturing facilities in San Dimas, California; Antwerp, Belgium; Lakewood, Colorado, and Boulder; and marketing subsidiaries worldwide.


NeXstar Pharmaceuticals

Related Antibody Articles from Brightsurf:

Antibody evolution may predict COVID-19 outcomes
For COVID-19, the difference between surviving and not surviving severe disease may be due to the quality, not the quantity, of the patients' antibody development and response, suggests a new study.

Can an antibody 'cocktail' prevent COVID-19 infection?
In a new COVID-19 clinical trial, Stuart Cohen at UC Davis Health tests monoclonal antibody combination to prevent COVID-19 in adults exposed to infected patients.

An in-depth analysis of antibody responses to SARS-CoV-2
Using a technology called VirScan to study coronavirus antibody responses in a large cohort of SARS-CoV-2-infected and control individuals, researchers identified epitopes recognized by a large fraction of COVID-19 patients, epitopes cross-reactive with antibodies developed in response to other human coronaviruses, and 10 epitopes likely recognized by neutralizing antibodies.

Tracking antibody profiles for influenza exposures across the lifespan
Immune responses to influenza exposures increase early in life, then decline in middle age, according to a study published July 23 in the open-access journal PLOS Pathogens by Bingyi Yang of the University of Florida, Steven Riley of Imperial College London, Derek Cummings of the University of Florida, and colleagues.

New study ranks performance of currently available COVID-19 antibody tests
Conducted by researchers at NSF International and Novateur Ventures, the peer-reviewed study finds significant variability in the accuracy of available COVID-19 antibody tests.

Ushering an antibody cocktail, designed to reduce antibody resistance, to trial as COVID-19 therapy
Following two studies that screened thousands of human antibodies to SARS-CoV-2 to identify highly potent pairs, in which the antibodies bind non-overlapping regions of the viral target, a resultant antibody cocktail is being tested in human trials.

COVID-19 antibody tests: How reliable are they?
With stay-at-home orders expiring around the world, many hope that COVID-19 antibody testing will help businesses and institutions reopen safely.

A faster way to make antibody-drug conjugates
In a study published today in Science Advances, USC scientists describe a new technology to rapidly create a homogeneous type of ADC, which attaches to a specific site on the cancer cell, with improved efficiency and potentially enhanced stability, effectiveness and safety.

Antibody designed to recognize pathogens of Alzheimer's disease
Researchers have found a way to design an antibody that can identify the toxic particles that destroy healthy brain cells -- a potential advance in the fight against Alzheimer's disease.

New technology can detect anti-virus antibody in 20 minutes
Researchers have succeeded in detecting anti-avian influenza virus antibody in blood serum within 20 minutes, using a portable analyzer they have developed to conduct rapid on-site bio tests.

Read More: Antibody News and Antibody Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.